On September 6, the "National Cancer Center Proton Therapy Academic Symposium and ISOP Proton Therapy International Symposium" hosted by the National Cancer Center and the Beijing Society of Oncology, hosted by the Cancer Hospital of the Chinese Academy of Medical Sciences, and co-organized by the IBA company was held at the Beijing International Hotel. This conference gathers top experts and scholars in the field of proton therapy around the world, and conducts in-depth dialogues on core issues such as technological frontiers, clinical practice and multidisciplinary collaboration, aiming to further promote international exchanges and cooperation in proton therapy technology, lead innovation and breakthroughs in the field of radiation therapy, and inject new impetus into the high-quality development of proton therapy technology in my country.
Chinese and foreign guests painted a new blueprint for proton therapy
The important guests attended the opening ceremony include: Academician of the Chinese Academy of Sciences, Director of the National Cancer Center, and Director of the Cancer Hospital of the Chinese Academy of Medical Sciences, Mr. Bruno Angelet, Ambassador of the Kingdom of Belgium to China, Academician Yu Jinming, Academician Olivier Legrain, President of IBA Company, Professor Wang Luhua, Director of the Shenzhen Hospital of the Cancer Hospital of the Chinese Academy of Medical Sciences, Professor Li Baosheng, Deputy Director of the Cancer Hospital of Shandong First Medical University, Frank RH, Trento Proton Therapy Center, Italy Professor Lohr, Professor Jeffrey Free, University Medical Center, Groningen, Netherlands, Professor Shannon MacDonald, Proton Therapy Center of South Florida, USA, Professor Leo Ding, Beaumont Medical Center, USA, and many well-known experts and scholars from home and abroad.
Academician Hejie pointed out in his speech: "In recent years, proton therapy technology has developed rapidly in my country. As of now, nearly 10 medical institutions have installed proton therapy systems in the country. It is expected that in the next 5 to 10 years, a large number of medical institutions will gradually be equipped with proton therapy equipment. Under this background, carrying out systematic training and learning and cultivating a professional and standardized talent team is crucial to ensuring the standardization and long-term development of proton therapy technology." Academician Hejie emphasized that the National Cancer Center has always undertaken the important responsibilities of national tumor prevention and control, diagnosis and treatment policies and scientific support, and has the responsibility to actively promote the standardization and popularization of proton therapy technology. As an important attempt, this conference invited 11 authoritative experts from top medical centers in the world. They will jointly discuss in-depth issues such as clinical experience, practical paths, and technological innovation of proton therapy. We hope that this conference can gather wisdom and jointly promote China's proton therapy industry to a new high ground for intelligence and internationalization.
In his speech, Ambassador Bruno Angelet highly praised China's great progress in the medical and health field under the guidance of the "Healthy China 2030" strategy. He pointed out that China has achieved remarkable results in the construction of the cancer prevention and control system and is gradually transforming from treatment to prevention and precision medicine. In this process, the introduction and localization of cutting-edge technologies such as proton therapy are of strategic significance. Ambassador Angelet emphasized that the summit has built a high-end exchange platform for Chinese and foreign experts, which will help promote pragmatic cooperation between China and leading international companies such as the IBA in the field of cancer treatment. He mentioned that although Belgium has a limited territory, it has global influence in life sciences, pharmaceutical research and development and logistics hubs. It is not only a major production center for many vaccines and pharmaceutical products, but also a key node for China-Europe trade and cooperation. He looks forward to further deepening cooperation with China in the fields of health technology and cancer prevention and control in the future, and jointly improving the global level of cancer diagnosis and treatment.
Olivier Legrain said in his welcome speech that IBA, as a pioneer in proton therapy technology, has installed more than 80 proton therapy systems around the world over the past 30 years, of which 7 are located in mainland China. With the rapid growth of China's demand for proton therapy, IBA has worked closely with its Chinese partners to promote the accessibility of proton therapy technology and benefit more patients. Olivier emphasized that technology can only be maximized by closely combining with clinical practice. IBA will continue to support Chinese and foreign clinical experts in carrying out knowledge exchange and capacity building, and fully release the technical potential of proton therapy. He wished the summit a fruitful result and looked forward to jointly promoting the development of proton therapy with his Chinese colleagues.
The opening ceremony was hosted by Professor Yi Junlin of the Cancer Hospital of the Chinese Academy of Medical Sciences.
Focus on precision and lead the change—Front-front progress and clinical practice of proton therapy in China and abroad
Many authoritative experts from China and abroad shared and discussed in-depth research, clinical practice and future development direction of proton therapy.
Academician Yu Jinming systematically sorted out the latest breakthroughs and development trends in the field of radiotherapy with the topic of "New Progress in Radiation Therapy", emphasizing that precise radiotherapy technology is profoundly changing the pattern of tumor treatment. Professor Frank R.H. Lohr gave a speech on "Patient Choice for Proton Therapy", exploring in-depth research on how to scientifically screen patients suitable for proton therapy to maximize efficacy. Professor Jeffrey Free reported on "Proton Therapy - Model-Based Method", demonstrating the important role of model-based proton therapy strategies in individualized diagnosis and treatment.
Professor Shannon MacDonald shared the "application of proton therapy in children's tumors", highlighting the significant advantages of proton therapy in the field of pediatric oncology, in the field of precise radiation dose control and protection of normal tissues. Professor Yi Junlin took the title "The Application of Proton Treatment in Head and Neck Tumors" as the topic, combined with clinical practice, and systematically explained the efficacy and clinical pathway of proton treatment in head and neck tumors. Professor Chen Jiayi gave a report on "The Application of Proton Therapy in Breast Tumors", emphasizing the clinical value of this technology in breast conservation treatment and reducing cardiotoxicity.
In this dialogue session, Chinese and foreign experts conducted in-depth exchanges from multiple dimensions such as international experience comparison, localization exploration, resource allocation, talent training, technology evolution, multi-center collaboration and industry-university-research integration, etc. The experts not only discussed the high-quality development path of proton therapy, its key ideas for implementation and system construction, but also discussed cutting-edge clinical research and innovative scientific research directions such as DynamicARC, and jointly planned new momentum and new paradigm for the leapfrog development of proton therapy.
Let's start a new journey together and move towards a new chapter in the high-quality development of proton therapy
This conference gathers top experts and scholars from China and abroad, covering a comprehensive range of content from basic research to clinical practice, from international experience to local innovation, and successfully built a high-level academic exchange platform. The meeting not only discussed the technical frontiers and clinical difficulties of proton therapy in depth, but also achieved important results in concept consensus, scientific research cooperation and talent training, injecting strong impetus into the standardization, internationalization and innovative development of my country's proton therapy industry. The successful holding of this ISOP Summit demonstrates China's confidence and strength to deeply integrate the world and lead the industry's development in the field of high-end medical technology, and will surely have a positive and far-reaching impact on the implementation of the Healthy China strategy and the global tumor prevention and control cause.
Source: Xinhuanet
